Certain heart meds may give chemo a boost

July 18, 2012 By Steven Reinberg, HealthDay Reporter
Certain heart meds may give chemo a boost
Digitalis, digoxin appear to trigger immune response that helps kill tumor cells, study shows.

(HealthDay) -- When common heart drugs such as digitalis and digoxin are combined with some chemotherapy drugs, the effect appears to be an increase in the death of cancer cells, according to French researchers.

These medications, called glycosides, have been around for decades and are used to treat and .

When combined with , however, they appear to act similar to a vaccine -- priming the immune system to kill .

"This is very exciting; it describes a new way to make chemotherapy more effective," said Marc Symons, an investigator at the Center for Oncology and Cell Biology at the Feinstein Institute for Medical Research in Manhasset, N.Y. Symons was not involved in the study, which was published July 18 in the journal Science Translational Medicine.

The effect was first noticed when the French team, led by Laurie Menger from INSERM in Villejuif, combed through patients' medical records. They discovered that cancer patients undergoing chemotherapy who were also taking these drugs for heart trouble tended to do better than cancer patients who did not take them.

The authors said this appears to be because the drugs convert dead cancer cells into a kind of trigger that alerts the immune system to attack .

This approach to still needs to be tested, however, and the researchers said they plan to do so in patients with neck and .

William Chambers, director of and Immunology at the , noted that the researchers also have developed a way of screening drugs to see if they will have this effect on cancer cells. That could help spot drugs that trigger an immune response, he said.

"It also reinforces the notion that the immune system and chemotherapy working in concert is really going to be important for effective treatments for cancer," he said. "Immunotherapy for cancer has been a 'sweet spot' in the last couple of years. A lot has been happening there."

"We have learned a lot about the immune response to cancer," he added. "There is a lot of potential here and I expect we are going to see a good bit more looking at this phenomenon."

One of the unanswered questions is what the effect will be of using these heart drugs on cancer patients with healthy hearts.

"Digoxin and similar drugs have effects on the heart that could be side effects in patients with normal hearts," said Dr. Kirk Garratt, director of interventional cardiovascular research at Lenox Hill Hospital in New York City.

These effects could pose a problem for these patients, he said, "but right now I don't see this as a problem in pursuing this research."

Garratt cautioned chemotherapy patients that not enough is known to add these drugs to their treatment at this point in time.

"It's too early to take that action," he said. "We don't know what side-effect issues might surface. We don't know what the downside will be, and there is always a downside."

For heart patients, however, these drugs are very safe, Garratt said. And there's another up side, he added: Since these drugs have been around for years, they are generic and inexpensive.

Although the study revealed an association between the use of these and an increase in the death of cancer cells, it did not prove a cause-and-effect relationship.

Explore further: Patients treated with sunitinib and sorafenib respond to flu vaccine

More information: To learn more about cancer immunotherapies, visit the American Cancer Society.

Related Stories

Patients treated with sunitinib and sorafenib respond to flu vaccine

June 28, 2011
Patients treated with sunitinib and sorafenib responded to the flu vaccine, which suggests the agents do not damage the immune system as much as previously feared, according to a study in Clinical Cancer Research, a journal ...

Evolving ovarian cancer cells 'dodge' treatment with chemotherapy

December 20, 2011
(Medical Xpress) -- Cancer Research UK scientists have discovered that the commonest type of ovarian cancer evolves at a startling rate, which may allow cancer cells to ‘dodge’ the current standard treatment, reveals ...

Nutritional supplement works against some pancreatic cancer cells in mice

April 3, 2012
The dietary supplement gamma-linoleic acid can inhibit the growth of a subset of pancreatic cancer cells and selectively promote cancer cell death in mice, a Mayo Clinic study has found. The supplement, a fatty acid also ...

Recommended for you

Alternative splicing, an important mechanism for cancer

September 22, 2017
Cancer, which is one of the leading causes of death worldwide, arises from the disruption of essential mechanisms of the normal cell life cycle, such as replication control, DNA repair and cell death. Thanks to the advances ...

'Labyrinth' chip could help monitor aggressive cancer stem cells

September 21, 2017
Inspired by the Labyrinth of Greek mythology, a new chip etched with fluid channels sends blood samples through a hydrodynamic maze to separate out rare circulating cancer cells into a relatively clean stream for analysis. ...

Whole food diet may help prevent colon cancer, other chronic conditions

September 21, 2017
A diet that includes plenty of colorful vegetables and fruits may contain compounds that can stop colon cancer and inflammatory bowel diseases in pigs, according to an international team of researchers. Understanding how ...

Drug combination may improve impact of immunotherapy in head and neck cancer

September 21, 2017
Checkpoint inhibitor-based immunotherapy has been shown to be very effective in recurrent and metastatic head and neck cancer but only in a minority of patients. University of California San Diego School of Medicine researchers ...

New kinase detection method helps identify targets for developing cancer drugs

September 21, 2017
Purdue University researchers have developed a high-throughput method for matching kinases to the proteins they phosphorylate, speeding the ability to identify multiple potential cancer drug targets.

Brain cancer growth halted by absence of protein, study finds

September 20, 2017
The growth of certain aggressive brain tumors can be halted by cutting off their access to a signaling molecule produced by the brain's nerve cells, according to a new study by researchers at the Stanford University School ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.